Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sharlene Gill

Showing results (11-20 of 154) with videos related to

Pageof 16
Sort By:
Cancer Metastasis Reviews|March 6, 2004
Role of cyclooxygenase-2 in colorectal cancerFrank A Sinicrope, Sharlene Gill
Drugs|January 16, 2004
First-line treatment strategies to improve survival in patients with advanced colorectal cancerSharlene Gill, Richard M Goldberg
Cancer Chemotherapy and Pharmacology|August 17, 2004
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancerRichard M Goldberg, Sharlene Gill
Nature Reviews. Clinical Oncology|June 30, 2009
Cetuximab, chemotherapy and KRAS status in mCRCSharlene Gill, Richard M Goldberg
Nature Clinical Practice. Oncology|November 3, 2005
Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?Sharlene Gill, Richard M Goldberg
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 18, 2017
Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review studyAaron Sha, Shirin Abadi, Sharlene Gill
Clinical Colorectal Cancer|November 28, 2008
Trends in chemotherapy utilization for colorectal cancerDaniel Renouf, Hagen Kennecke, Sharlene Gill
American Journal of Clinical Oncology|March 2, 2011
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experienceChristina Kim, David Owen, Sharlene Gill
Current Oncology (Toronto, Ont.)|December 13, 2021
Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical OncologistsSelina K Wong, Lovedeep Gondara, Sharlene Gill
Current Treatment Options in Oncology|August 28, 2003
New targeted therapies in gastrointestinal cancersSharlene Gill, Rebecca R Thomas, Richard M Goldberg
Pageof 16

Showing results (11-20 of 154) with videos related to

Sort By:
Pageof 16
Cancer Metastasis Reviews|March 6, 2004
Role of cyclooxygenase-2 in colorectal cancerFrank A Sinicrope, Sharlene Gill
Drugs|January 16, 2004
First-line treatment strategies to improve survival in patients with advanced colorectal cancerSharlene Gill, Richard M Goldberg
Cancer Chemotherapy and Pharmacology|August 17, 2004
Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancerRichard M Goldberg, Sharlene Gill
Nature Reviews. Clinical Oncology|June 30, 2009
Cetuximab, chemotherapy and KRAS status in mCRCSharlene Gill, Richard M Goldberg
Nature Clinical Practice. Oncology|November 3, 2005
Duration of adjuvant therapy for colorectal cancer: are we overtreating our patients?Sharlene Gill, Richard M Goldberg
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|July 18, 2017
Utilization of capecitabine plus oxaliplatin and 5-fluorouracil/folinic acid plus oxaliplatin in the adjuvant treatment of stage IIB and stage III colon cancer: A multi-centre, retrospective, chart review studyAaron Sha, Shirin Abadi, Sharlene Gill
Clinical Colorectal Cancer|November 28, 2008
Trends in chemotherapy utilization for colorectal cancerDaniel Renouf, Hagen Kennecke, Sharlene Gill
American Journal of Clinical Oncology|March 2, 2011
Real-world impact of availability of adjuvant therapy on outcomes in patients with resected pancreatic adenocarcinoma: a Canadian Cancer Agency experienceChristina Kim, David Owen, Sharlene Gill
Current Oncology (Toronto, Ont.)|December 13, 2021
Current Attitudes toward Unfunded Cancer Therapies among Canadian Medical OncologistsSelina K Wong, Lovedeep Gondara, Sharlene Gill
Current Treatment Options in Oncology|August 28, 2003
New targeted therapies in gastrointestinal cancersSharlene Gill, Rebecca R Thomas, Richard M Goldberg
Pageof 16